High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer.
Inna ChervonevaAmy R PeckYunguang SunMisung YiSameer S UdhaneJohn F LangenheimMelanie A GirondoJulie M JornsLubna N ChaudharySailaja KamarajuCarmen BergomMichael J FlisterJeffrey A HookeAlbert J KovatichCraig D ShriverHai HuJuan P PalazzoMarluce BibboTerry HyslopMarja T NevalainenRichard G PestellSerge Y FuchsEdith P MitchellHallgeir RuiPublished in: JCO precision oncology (2023)
Up to one third of treatment-naive ER+ breast tumors expressed high PD-L2 levels, which independently predicted poor clinical outcome, with evidence of further elevated risk of progression in patients who received adjuvant chemotherapy. Collectively, these data warrant studies to gain a deeper understanding of PD-L2 in the progression of ER+ breast cancer and may provide rationale for immune checkpoint blockade for this patient group.